At a glance
ClinicalIndex Comparison RecordPhase 2Suspended· 30 target
Drug / intervention
utidelone injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer After Failure or Intolerability to Second-line Standard Treatment
In Brief
A Phase 2 clinical trial evaluating utidelone injection for Advanced or Metastatic CRC. Suspended, targeting 30 participants across 5 sites.
Signals
Trial is currently suspended
Detailed Summary
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic colorectal cancer (CRC) as a phase II trial
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic CRC
CountriesChina
CollaboratorsChengdu Biostar Pharmaceuticals
Timeline
Phase 2SuspendedOverdue
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionDec 2023
Study CompletionDec 2024
TodayJul 2026
First PostedApr 8, 2019
Enrollment StartApr 12, 2019
Primary CompletionDec 31, 2023
Study CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 7.2 years ago
Interventions
utidelone injectiondrug
utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection